Last reviewed · How we verify
Oseltamivir phosphate granules
Oseltamivir phosphate inhibits viral neuraminidase, preventing the release of influenza virus particles from infected cells and reducing viral spread.
Oseltamivir phosphate inhibits viral neuraminidase, preventing the release of influenza virus particles from infected cells and reducing viral spread. Used for Treatment of acute uncomplicated influenza A and B infection, Prophylaxis of influenza A and B in high-risk patients.
At a glance
| Generic name | Oseltamivir phosphate granules |
|---|---|
| Also known as | Reduning injection simulants, tamiflu,0221503013, TAMIFLU®, Tamiflu |
| Sponsor | China Academy of Chinese Medical Sciences |
| Drug class | Neuraminidase inhibitor |
| Target | Influenza neuraminidase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Oseltamivir is a prodrug that is converted to its active form (oseltamivir carboxylate) in the body. The active metabolite binds to and inhibits influenza virus neuraminidase, an enzyme responsible for cleaving sialic acid receptors on host cell surfaces. By blocking this enzyme, oseltamivir prevents newly formed viral particles from being released from infected cells, thereby limiting viral replication and transmission.
Approved indications
- Treatment of acute uncomplicated influenza A and B infection
- Prophylaxis of influenza A and B in high-risk patients
Common side effects
- Nausea
- Vomiting
- Abdominal pain
- Headache
- Diarrhea
Key clinical trials
- Clinical Study of Reduning Injection for the Treatment of Influenza in Children (PHASE4)
- Phase IIaTrials of GanMaoKangNing Granules (PHASE2)
- Banlangen Granules Anti-seasonal Influenza Study (PHASE4)
- Lingdancao Granules in the Treatment of Seasonal Influenza (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: